Rivaroxaban antithrombotics

BAY 59-7939 - Xarelto      

pdf
pathology Demonstrated benefit and harm k      
acute coronary syndrome

versus placebo or control

No demonstrated result for efficacy

rivaroxaban 2.5mg inferior to placebo in terms of major bleeding in ATLAS ACS 2 - TIMI 51 (2.5mg), 2011

rivaroxaban 2.5mg inferior to placebo in terms of ISTH major or clinically relevant nonmajor bleeding in ATLAS ACS 2 - TIMI 51 (2.5mg), 2011

rivaroxaban 2.5mg inferior to placebo in terms of any bleeding in ATLAS ACS 2 - TIMI 51 (2.5mg), 2011

rivaroxaban 2.5mg inferior to placebo in terms of major or minor bleeding in ATLAS ACS 2 - TIMI 51 (2.5mg), 2011

rivaroxaban 5mg inferior to placebo in terms of major bleeding in ATLAS ACS 2 - TIMI 51 (5mg), 2011

rivaroxaban 5mg inferior to placebo in terms of ISTH major or clinically relevant nonmajor bleeding in ATLAS ACS 2 - TIMI 51 (5mg), 2011

rivaroxaban 5mg inferior to placebo in terms of any bleeding in ATLAS ACS 2 - TIMI 51 (5mg), 2011

rivaroxaban 5mg inferior to placebo in terms of major bleeding in ATLAS ACS-TIMI 46 (5mg), 2009

rivaroxaban 5mg inferior to placebo in terms of ISTH major or clinically relevant nonmajor bleeding in ATLAS ACS-TIMI 46 (5mg), 2009

4 trialsmeta-analysis
atrial fibrillation

versus anticoagulant

No demonstrated result for efficacy

rivaroxaban inferior to warfarin standard dose in terms of Gastrointestinal major bleeding in ROCKET-AF, 2010

2 trialsmeta-analysis
cardiovascular prevention

versus

No demonstrated result for efficacy

rivaroxaban + aspirin inferior to aspirin in terms of major bleeding in COMPASS (rivaroxaban + aspirin), 2017 (secondary prevention patients)

rivaroxaban + aspirin inferior to aspirin in terms of CV events in COMPASS (rivaroxaban + aspirin), 2017 (secondary prevention patients)

rivaroxaban + aspirin inferior to aspirin in terms of all causes deaths in COMPASS (rivaroxaban + aspirin), 2017 (secondary prevention patients)

rivaroxaban + aspirin inferior to aspirin in terms of CV death (IHD+stroke) in COMPASS (rivaroxaban + aspirin), 2017 (secondary prevention patients)

rivaroxaban + aspirin inferior to aspirin in terms of fatal stroke in COMPASS (rivaroxaban + aspirin), 2017 (secondary prevention patients)

rivaroxaban + aspirin inferior to aspirin in terms of ischemic stroke in COMPASS (rivaroxaban + aspirin), 2017 (secondary prevention patients)

rivaroxaban + aspirin inferior to aspirin in terms of all stroke in COMPASS (rivaroxaban + aspirin), 2017 (secondary prevention patients)

2 trialsmeta-analysis
heart failure

versus

No demonstrated result for efficacy

1 trialmeta-analysis
post stroke

versus

No demonstrated result for efficacy

1 trialmeta-analysis
pulmonary embolism

versus heparin/VKA

No demonstrated result for efficacy

1 trialmeta-analysis
thrombosis prevention

versus

No demonstrated result for efficacy

rivaroxaban inferior to placebo in terms of Clinically relevant bleeding in MARINER, 2018 (medical patients patients)

1 trialmeta-analysis
thrombosis prevention

versus Low molecular weight heparin

No demonstrated result for efficacy

6 trialsmeta-analysis
venous thrombosis

versus

No demonstrated result for efficacy

rivaroxaban inferior to dalteparin in terms of all bleeding in SELECT D, 2018 (patients with cancer patients)

2 trialsmeta-analysis
venous thrombosis

versus discontinuation

No demonstrated result for efficacy

rivaroxaban inferior to discontinuation in terms of major or clinically relevant nonmajor bleeding in EINSTEIN-extension, 2009

1 trialmeta-analysis
venous thrombosis

versus heparin/VKA

No demonstrated result for efficacy

3 trialsmeta-analysis